BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Shimada M, Miyagawa T, Kodama T, Toyoda H, Tokunaga K, Honda M. Metabolome analysis using cerebrospinal fluid from narcolepsy type 1 patients. Sleep 2020;43:zsaa095. [PMID: 32412602 DOI: 10.1093/sleep/zsaa095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nirogi R, Ajjala DR, Prakash Padala NS, Kalaikadhiban I, Rayapati LP, Chunduru P, Shinde A. LC-MS/MS method for the quantification of SUVN-G3031, a novel H3 receptor inverse agonist for narcolepsy treatment. Bioanalysis 2020;12:533-44. [PMID: 32351118 DOI: 10.4155/bio-2020-0020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cuomo MC, Sheehan AH, Jordan JK. Solriamfetol for the Management of Excessive Daytime Sleepiness. J Pharm Pract 2021;:8971900211009080. [PMID: 33882756 DOI: 10.1177/08971900211009080] [Reference Citation Analysis]
4 Caputo F, Cibin M, Loche A, De Giorgio R, Zoli G. The recognition and management of protracted alcohol withdrawal may improve and modulate the pharmacological treatment of alcohol use disorder. J Psychopharmacol 2020;34:1171-5. [PMID: 32648800 DOI: 10.1177/0269881120936483] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials. Sleep Med 2020;75:510-21. [PMID: 33032062 DOI: 10.1016/j.sleep.2020.09.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Davis CW, Kallweit U, Schwartz JC, Krahn LE, Vaughn B, Thorpy MJ. Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies. Sleep Med 2021;81:210-7. [PMID: 33721598 DOI: 10.1016/j.sleep.2021.02.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ghorbanzadeh H, Mohebkhodaei P, Nematizadeh M, Rahimi N, Rafeiean M, Ghasemi M, Dehpour AR. Analgesic and anti-inflammatory effects of modafinil in a mouse model of neuropathic pain: A role for nitrergic and serotonergic pathways. Neurol Res 2021;:1-13. [PMID: 34706635 DOI: 10.1080/01616412.2021.1992102] [Reference Citation Analysis]
8 Kim H, Cho JW. Narcolepsy, How do We Manage it? J Sleep Med 2020;17:1-10. [DOI: 10.13078/jsm.200006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 D'Anselmo A, Agnoli S, Filardi M, Pizza F, Mastria S, Corazza GE, Plazzi G. Creativity in Narcolepsy Type 1: The Role of Dissociated REM Sleep Manifestations. Nat Sci Sleep 2020;12:1191-200. [PMID: 33364866 DOI: 10.2147/NSS.S277647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 de Biase S, Pellitteri G, Gigli GL, Valente M. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother 2021;22:155-62. [PMID: 32941089 DOI: 10.1080/14656566.2020.1817387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
11 Ohayon MM, Thorpy MJ, Carls G, Black J, Cisternas M, Pasta DJ, Bujanover S, Hyman D, Villa KF. The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis. Sleep Med 2021;84:405-14. [PMID: 34304148 DOI: 10.1016/j.sleep.2021.06.008] [Reference Citation Analysis]
12 Meskill GJ, Kallweit U, Zarycranski D, Caussé C, Finance O, Ligneau X, Davis CW. Pitolisant for the treatment of cataplexy in adults with narcolepsy. Expert Opinion on Orphan Drugs. [DOI: 10.1080/21678707.2021.2022472] [Reference Citation Analysis]
13 Dye TJ, Simakajornboon N. Narcolepsy in Children: Sleep disorders in children, A rapidly evolving field seeking consensus. Pediatr Pulmonol 2021. [PMID: 34021733 DOI: 10.1002/ppul.25512] [Reference Citation Analysis]
14 Anderson D. Narcolepsy: A clinical review. JAAPA 2021;34:20-5. [PMID: 34031309 DOI: 10.1097/01.JAA.0000750944.46705.36] [Reference Citation Analysis]
15 Dondé C, Polosan M, Guzun R. Pitolisant for Treating Narcolepsy Comorbid With Schizophrenia. J Clin Psychopharmacol 2020;40:504-6. [DOI: 10.1097/jcp.0000000000001243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zomorodi K, Chen D, Lee L, Swearingen D, Carter LP. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. Clin Pharmacol Drug Dev 2021;10:404-13. [PMID: 32935460 DOI: 10.1002/cpdd.867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Xiao L, Chen A, Parmar A, Frankel L, Toulany A, Murray BJ, Narang I. Narcolepsy Treatment: Voices of Adolescents. Behav Sleep Med 2021;:1-9. [PMID: 33877929 DOI: 10.1080/15402002.2021.1916496] [Reference Citation Analysis]
18 Meskill GJ, Davis CW, Zarycranski D, Doliba M, Schwartz JC, Dayno JM. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials. CNS Drugs 2021. [PMID: 34935103 DOI: 10.1007/s40263-021-00886-x] [Reference Citation Analysis]
19 Parmar A, Murray BJ, Narang I. Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy. Curr Neurol Neurosci Rep 2020;20:38. [PMID: 32651734 DOI: 10.1007/s11910-020-01057-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pérez-carbonell L, Lyons E, Gnoni V, Higgins S, Otaiku AI, Leschziner GD, Drakatos P, d’Ancona G, Kent BD. Adherence to wakefulness promoting medication in patients with narcolepsy. Sleep Medicine 2020;70:50-4. [DOI: 10.1016/j.sleep.2020.02.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Flores-Clemente C, Nicolás-Vázquez MI, Mera Jiménez E, Hernández-Rodríguez M. Inhibition of Astrocytic Histamine N-Methyltransferase as a Possible Target for the Treatment of Alzheimer's Disease. Biomolecules 2021;11:1408. [PMID: 34680041 DOI: 10.3390/biom11101408] [Reference Citation Analysis]
22 Pellitteri G, de Biase S, Valente M, Gigli GL. How treatable is narcolepsy with current pharmacotherapy and what does the future hold? Expert Opin Pharmacother 2021;22:1517-20. [PMID: 33882765 DOI: 10.1080/14656566.2021.1915987] [Reference Citation Analysis]
23 Bjorvatn B, Jernelöv S, Pallesen S. Insomnia - A Heterogenic Disorder Often Comorbid With Psychological and Somatic Disorders and Diseases: A Narrative Review With Focus on Diagnostic and Treatment Challenges. Front Psychol 2021;12:639198. [PMID: 33643170 DOI: 10.3389/fpsyg.2021.639198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Thomas EM, Freeman TP, Poplutz P, Howden K, Hindocha C, Bloomfield M, Kamboj SK. Stimulating meditation: a pre-registered randomised controlled experiment combining a single dose of the cognitive enhancer, modafinil, with brief mindfulness training. J Psychopharmacol 2021;35:621-30. [PMID: 33645313 DOI: 10.1177/0269881121991835] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zaccara G, Bartolini E, Tramacere L, Lattanzi S. Drugs for patients with epilepsy and excessive daytime sleepiness. Epilepsy Behav 2021;124:108311. [PMID: 34534876 DOI: 10.1016/j.yebeh.2021.108311] [Reference Citation Analysis]
26 Jennum PJ, Plazzi G, Silvani A, Surkin LA, Dauvilliers Y. Cardiovascular disorders in narcolepsy: Review of associations and determinants. Sleep Med Rev 2021;58:101440. [PMID: 33582582 DOI: 10.1016/j.smrv.2021.101440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]